| Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients E Ferrannini, E Muscelli, S Frascerra, S Baldi, A Mari, T Heise, UC Broedl, ... The Journal of clinical investigation 124 (2), 499-508, 2014 | 1181 | 2014 |
| A model-based method for assessing insulin sensitivity from the oral glucose tolerance test A Mari, G Pacini, E Murphy, B Ludvik, JJ Nolan Diabetes care 24 (3), 539-548, 2001 | 937 | 2001 |
| How to measure insulin sensitivity E Ferrannini, A Mari Journal of hypertension 16 (7), 895-906, 1998 | 677 | 1998 |
| β-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis E Ferrannini, A Gastaldelli, Y Miyazaki, M Matsuda, A Mari, RA DeFronzo The Journal of Clinical Endocrinology & Metabolism 90 (1), 493-500, 2005 | 672 | 2005 |
| Shift to fatty substrate utilization in response to sodium–glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes E Ferrannini, S Baldi, S Frascerra, B Astiarraga, T Heise, R Bizzotto, ... Diabetes 65 (5), 1190-1195, 2016 | 647 | 2016 |
| Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery C Guidone, M Manco, E Valera-Mora, A Iaconelli, D Gniuli, A Mari, ... Diabetes 55 (7), 2025-2031, 2006 | 509 | 2006 |
| Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients E Muscelli, A Mari, A Casolaro, S Camastra, G Seghieri, A Gastaldelli, ... Diabetes 57 (5), 1340-1348, 2008 | 507 | 2008 |
| Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients E Muscelli, A Mari, A Casolaro, S Camastra, G Seghieri, A Gastaldelli, ... Diabetes 57 (5), 1340-1348, 2008 | 505 | 2008 |
| Pancreatic fat content and β-cell function in men with and without type 2 diabetes ME Tushuizen, MC Bunck, PJ Pouwels, S Bontemps, ... Diabetes care 30 (11), 2916-2921, 2007 | 501 | 2007 |
| Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes A Mari, WM Sallas, YL He, C Watson, M Ligueros-Saylan, BE Dunning, ... The Journal of Clinical Endocrinology & Metabolism 90 (8), 4888-4894, 2005 | 481 | 2005 |
| Positive Wigner functions render classical simulation of quantum computation efficient A Mari, J Eisert Physical review letters 109 (23), 230503, 2012 | 437 | 2012 |
| Robust entanglement of a micromechanical resonator with output optical fields C Genes, A Mari, P Tombesi, D Vitali Physical Review A 78 (3), 032316, 2008 | 377 | 2008 |
| Visceral fat in hypertension: influence on insulin resistance and β-cell function AM Sironi, A Gastaldelli, A Mari, D Ciociaro, V Postano, E Buzzigoli, ... Hypertension 44 (2), 127-133, 2004 | 374 | 2004 |
| Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance E Ferrannini, A Natali, S Camastra, M Nannipieri, A Mari, KP Adam, ... Diabetes 62 (5), 1730-1737, 2013 | 369 | 2013 |
| Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance E Ferrannini, A Natali, S Camastra, M Nannipieri, A Mari, KP Adam, ... Diabetes 62 (5), 1730-1737, 2013 | 369 | 2013 |
| Meal and oral glucose tests for assessment of β-cell function: modeling analysis in normal subjects A Mari, O Schmitz, A Gastaldelli, T Oestergaard, B Nyholm, E Ferrannini American Journal of Physiology-Endocrinology and Metabolism 283 (6), E1159-E1166, 2002 | 362 | 2002 |
| Methods for clinical assessment of insulin sensitivity and β-cell function G Pacini, A Mari Best practice & research Clinical endocrinology & metabolism 17 (3), 305-322, 2003 | 357 | 2003 |
| Gently modulating optomechanical systems A Mari, J Eisert Physical Review Letters 103 (21), 213603, 2009 | 351 | 2009 |
| Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones M Nannipieri, S Baldi, A Mari, D Colligiani, D Guarino, S Camastra, ... The Journal of Clinical Endocrinology & Metabolism 98 (11), 4391-4399, 2013 | 339 | 2013 |
| The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients B Balas, MR Baig, C Watson, BE Dunning, M Ligueros-Saylan, Y Wang, ... The Journal of Clinical Endocrinology & Metabolism 92 (4), 1249-1255, 2007 | 305 | 2007 |
